` 42C (IX Biopharma Ltd) vs FTSE Straits Times Singapore Comparison - Alpha Spread

42C
vs
FTSE Straits Times Singapore

Over the past 12 months, 42C has outperformed FTSE Straits Times Singapore, delivering a return of -58% compared to the FTSE Straits Times Singapore's 0% growth.

Stocks Performance
42C vs FTSE Straits Times Singapore

Loading
42C
FTSE Straits Times Singapore
Add Stock

Performance Gap
42C vs FTSE Straits Times Singapore

Loading
42C
FTSE Straits Times Singapore
Difference

Performance By Year
42C vs FTSE Straits Times Singapore

Loading
42C
FTSE Straits Times Singapore
Add Stock

Competitors Performance
IX Biopharma Ltd vs Peers

FTSE Straits Times Singapore
42C
LLY
JNJ
NOVO B
ROG
Add Stock

IX Biopharma Ltd
Glance View

Market Cap
15m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
0.029 SGD
Undervaluation 42%
Intrinsic Value
Price
I
Back to Top